Study of 750,000 pregnancies reveals a surprising twist about Ozempic and Wegovy

A study of 750,000 pregnancies suggests that GLP-1 receptor agonists like Ozempic and Wegovy do not inherently increase the risk of premature birth. Researchers found that complications were linked to the underlying diabetes condition rather than the medication itself.
Why it matters
This provides critical safety context for the millions of people using popular weight-loss drugs, helping to clarify risks for those who may become pregnant while on the medication.
A major study involving more than 750,000 pregnancies has uncovered an important difference in the potential pregnancy risks of popular weight loss medications such as Ozempic and Wegovy. Women who unintentionally used these drugs shortly before or during early pregnancy were more likely to give birth prematurely, but only when the medications had been prescribed to treat existing diabetes.
Among women taking the same medications for weight management, researchers found no significant association with premature birth or other pregnancy complications examined in the study.
The findings suggest that diabetes itself, rather than the medications, may be responsible for the increased risk of early delivery. The research was published in Human Reproduction Open , a leading journal in reproductive medicine.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in